Dr Andrew Robinson speaks to ecancer about the 3-year follow-up from KEYNOTE-407 regarding first-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC.
Initially, he explains the rationale behind the study.
Dr Robison then, discusses the key results from this study and what impact can these results have on the treatment of advanced squamous NSCLC.
This 3 year of follow-up showed that pembro chemo continued to demonstrate durable benefit vs chemo alone without additional toxicity. Most patients who completed 35 cycles had objective responses and were alive at data cutoff.
In the end, Dr Robinson says that this data continues to support pembro chemo as first-line treatment in patients with metastatic squamous NSCLC.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.